New parenteral anticoagulants in development

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 1, 2011, Pages 33-59

  Gómez Outes, Antonio ^a   Suárez Gea, Maria Luisa ^a   Pozo Hernández, Carmen ^a   Lecumberri, Ramón ^b   Rocha, Eduardo ^b   Vargas Castrillón, Emilio ^c  

^a Parque Empresarial Las Mercedes   (Colombia)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Department of Clinical Pharmacology   (Colombia)

Author keywords

Anticoagulants; EP217609; Flovagatran; Heparin; Idrabiotaparinux; Otamixaban; Pegmusirudin; RB 006; Semuloparin; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; ARGATROBAN; AVIDIN; BMS 262084; CLAVATADINE; DESULFATOHIRUDIN; DROTRECOGIN; ENOXAPARIN; EP 5001; EPTIFIBATIDE; FLOVAGATRAN; FONDAPARINUX; FXV 673; GSK 576428; HD 1 22; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; IDRABIOTAPARINUX; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LU 87981; M 118; MONOCLONAL ANTIBODY LE2E9; NU 172; OTAMIXABAN; PEGMUSIRUDIN; PLACEBO; RPR 130673; SEMULOPARIN; SPP 200; TANOGITRAN; TB 402; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ANTIDOTE; NEW DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CAROTID ARTERY THROMBOSIS; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERKALEMIA; LOADING DRUG DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STROKE; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; INFUSION; INJECTION; RISK ASSESSMENT; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; ANTIDOTES; BLOOD COAGULATION; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HEMORRHAGE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79551711217     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944710387808     Document Type: Review

References (170)

1. Abraham E. Reinhart K. Svoboda P. Seibert A. Olthoff D. Dal Nogare A. et al (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29: 2081–2089.
2. Abraham E. Reinhart K. Opal S. Demeyer I. Doig C. Rodriguez A.L. et al (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238–247.
3. Abraham E. Laterre P.F. Garg R. Levy H. Talwar D. Trzaskoma B.L. et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332–1341.
4. Ahrens I. Lip G.Y. Peter K. (2010) New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 104: 49–60.
5. Alban S. (2005) The ‘precautionary principle’ as a guide for future drug development. Eur J Clin Invest 35(Suppl. 1): 33–44.
6. Ansell J. (2007) Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 5(Suppl. 1): 60–64.
7. Ansell J. Hirsh J. Hylek E. Jacobson A. Crowther M. Palareti G. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 160S–198S.
8. Antonijoan R.M. Rico S. Puntes M. Borrell M. Fontcuberta J. Monreal M. et al (2009) Pharmacokinetics and safety of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers–a first time in human (FTIH) single ascending dose study. J Thromb Haemost 7(Suppl. 2): PP-WE-178 [Abstract].
9. Armstrong J.K. Hempel G. Koling S. Chan L.S. Fisher T. Meiselman H.J. et al (2007) Antibody against polyethylene glycol adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110: 103–111.
10. Avgerinos G.C. Turner B.G. Gorelick K.J. Papendieck A. Weydemann U. Gellissen G. (2001) Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin. Semin Thromb Hemost 27: 357–372.
11. Barton P. Kalil A.C. Nadel S. Goldstein B. Okhuysen-Cawley R. Brilli R.J. et al (2004) Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 113: 7–17.
12. Bates S.M. Greer I.A. Pabinger I. Sofaer S. Hirsh J. for the American College of Chest Physicians (2008) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 844S–886S.
13. Becker R.C. Povsic T. Cohen M.G. Rusconi C.P. Sullenger B. (2010) Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics. Thromb Haemost 103: 586–595.
14. Bellamy L. Rosencher N. Eriksson B. (2009) Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer Adherence 3: 173–177.
15. Bernard G.R. Vincent J.L. Laterre P.F. LaRosa S.P. Dhainaut J.F. Lopez-Rodriguez A. et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709.
16. Buchanan M.S. Carroll A.R. Wessling D. Jobling M. Avery V.M. Davis R.A. et al (2008) Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem 51: 3583–3587.
17. Buller H.R. Destors J.M. Gallus A.S. Prins M.H. Raskob G.E. (2008) Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): Safety, efficacy, and reversibility by avidin. Blood (ASH Annual Meeting Abstracts) 112: 18 (Abstract 32).
18. Camerota A.J. Creasey A.A. Patla V. Larkin V.A. Fink M.P. (1998) Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram negative peritonitis. J Infect Dis 177: 668–676.
19. Cappello M. Vlasuk G.P. Bergum P.W. Huang S. Hotez P.J. (1995) Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 92: 6152–6156.
20. Carr C. Bild G.S. Chang A.C. Peer G.T. Palmier M.O. Frazier R.B. et al (1995) Recombinant E coli derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram negative model of septic shock. Circ Shock 44: 126–137.
21. Chahwala S. Chander C. (2005) Identification and in vitro characterization of TGN 255, a novel synthetic intravenous low molecular weight direct thrombin inhibitor. J Thromb Haemost 3(Suppl.1): P2306 [abstract].
22. Chan M.Y. Cohen M.G. Dyke C.K. Myles S.K. Aberle L.G. Lin M. et al (2008 a) Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117: 2865–2874.
23. Chan M.Y. Rusconi C.P. Alexander J.H. Tonkens R.M. Harrington R.A. Becker R.C. (2008 b) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 6: 789–796.
24. Cohen A.T. Agnelli G. Anderson F.A. Arcelus J.I. Bergqvist D. Brecht J.G. et al (2007 a) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98: 756–764.
25. Cohen M. Bhatt D.L. Alexander J.H. Montalescot G. Bode C. Henry T. et al (2007 b) Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115: 2642–2651.
26. Cohen M.G. Purdy D.A. Rossi J.S. Grinfeld L.R. Myles S.K. Aberle L.H. et al (2010) First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 122: 614–622.
27. Combe S. Allen G. Kennedy A. (2005 a) Pharmacokinetics of TGN 255, a novel intravenous low molecular weight direct thrombin inhibitor, in healthy volunteers. J Thromb Haemost 3(Suppl. 1): P 1714 [abstract].
28. Combe S. Chander C. Kennedy A. (2005 b) Pharmacodynamics of TGN 255, a novel intravenous low molecular weight direct thrombin inhibitor, in healthy subjects. J Thromb Haemost 3(Suppl. 1): P 1115 [abstract].
29. Combe S. Kennedy A. Allen G. (2006 a) Phase 1 interaction study between TGN 255, a direct thrombin inhibitor, and aspirin plus clopidogrel. Eur Heart J 27(Suppl. 1): 762 [Abstract P4572].
30. Combe S. D'Souza R. Mysliwiec M. Padmanabhan N. Thomas M. Villa G. et al (2006 b) A phase IIa study to evaluate the safety, pharmacodynamics and pharmacokinetics of TGN 255 in stable haemodialysis patients. Nephrol Dial Transplant 21(Suppl. 4): SP 595 [abstract].
31. Committee for Medicinal Products for Human Use (CHMP) (2007) Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. CPMP/EWP/707/98 Rev.1 corr. Available at: http://www.ema.europa.eu (accessed 23 June 2010).
32. Creasey A.A. (1999) New potential therapeutic modalities: tissue factor pathway inhibitor. Sepsis 3: 173–182.
33. Crosby J. Gao D. Zhao C. Bhattacharjee G. May C. Zhang H. et al (2009) Systematic evaluation of coagulation factors as targets for anti-thrombotic therapy using antisense technology. Blood (ASH Annual Meeting Abstracts) 114: abstract 4181.
34. Davie E.W. Kulman J.D. (2006) An overview of the structure and function of thrombin. Semin Thromb Hemost 32: 3–15.
35. Desai U. (2009 / 2010) A novel sulfated low molecular weight lignin inhibits thrombin in a specific and allosteric manner to induce potent antithrombotic effect. Pathophysiol Haemos Thromb 37(Suppl. 1): P 54 [abstract].
36. Dewerchin M. van der Elst L. Singh I. Grailly S. Saint-Remy J.M. Collen D. et al (2004) Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice. J Thromb Haemost 2: 77–84.
37. Dubruc, C., Karimi-Anderesi, N., Lunven, C., Zhang, M., Grossmann, M. and Potgieter, H. (2009) Pharmacokinetics of a new, ultra-low molecular weight heparin, semuloparin (AVE5026), in healthy subjects. Results from the first phase I studies. 51th ASH Annual Meeting. Poster: 1073. Available at: http://ash.confex.com/ash/2009/webprogram/Paper22065.html (accessed 23 June 2010).
38. Dyke C.K. Steinhubl S.R. Kleiman N.S. Cannon R.O. Aberle L.G. Lin M. et al (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114: 2490–2497.
39. Eikelboom J.W. Weitz J.I. (2010) New anticoagulants. Circulation 121: 1523–1532.
40. Eikelboom J.W. Zelenkofske S.L. Rusconi C.P. (2010) Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 30: 382–387.
41. Esser N. Fiedler U. Graeser R. (2009) Antitumor efficacy of PEG-Hirudin, administered three times weekly, in an orthotopic AsPC-1 pancreas carcinoma model. Mol Cancer Ther 8(Meeting Abstract Suppl): C 183 [abstract].
42. Esslinger H.U. Haas S. Maurer R. Lassmann A. Dübbers K. Müller-Peltzer H. (1997) Pharmacodynamic and safety results of PEG-Hirudin in healthy subjects. Thromb Haemost 77: 911–919.
43. European Medicines Agency (2010 a) Angiox® Summary of Product Characteristics. Available at: http://www.ema.europa.eu (accessed 23 June 2010).
44. European Medicines Agency (2010 b) Pradaxa® Summary of Product Characteristics. Available at: http://www.ema.europa.eu (accessed 20 September 2010).
45. European Medicines Agency (2010 c) Revasc® Summary of Product Characteristics. Available at: http://www.ema.europa.eu (accessed 23 June 2010).
46. European Medicines Agency (2010 d) Xarelto® Summary of Product Characteristics. Available at: http://www.ema.europa.eu (accessed 20 September 2010).
47. European Medicines Agency (2010 e) Xigris® Summary of Product Characteristics. Available at: http://www.ema.europa.eu (accessed 23 June 2010).
48. Fisher W. Agnelli G. George D. Kakkar A. Lassen M.R. Mismetti P. et al (2009 / 2010 a) The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after hip fracture surgery. Pathophysiol Haemos Thromb 37(Suppl. 1): P 330 [abstract].
49. Fisher W. Agnelli G. George D. Kakkar A.K. Lassen M.R. Mismetti P. et al (2009 / 2010 b) Extended venous thromboembolism (VTE) prophylaxis after hip fracture surgery with the ultra-low-molecular-weight heparin (ULMWH) semuloparin. Pathophysiol Haemos Thromb 37(Suppl. 1): OC 681 [abstract].
50. Fromes, I., Neuhart, E., Krezel, C., Gueret, P. and Petitou, M. (2010) EP217609, a new neutralizable anticoagulant for cardiopulmonary bypass during cardiac surgery. In Proceedings of the 65th Congress of the French Society for Thoracic and Cardiovascular Surgery, Abstract C-10. Available at: http://www.congres-sfctcv.fr (accessed 23 June 2010).
51. Geerts W.H. Bergqvist D. Pineo G.F. Heit J.A. Samama C.M. Lassen M.R. et al (2008) Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 381S–453S.
52. Gill R. Herbertson M. Vuylsteke A. Olsen P.S. von Heymann C. Mythen M. et al (2009) Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 120: 21–27.
53. Giugliano R.P. Wiviott S.D. Stone P.H. Simon D.I. Schweiger M.J. Bouchard A. et al (2007) Recombinant nematode anticoagulant protein c 2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 49: 2398–2407.
54. Goldsack N.R. Chambers R.C. Dabbagh K. Laurent G.J. (1998) Thrombin. Int J Biochem Cell Biol 1998 30: 641–646.
55. Goldstein B. Nadel S. Peters M. Barton R. Machado F. Levy H. et al (2006) ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr Crit Care Med 7: 200–211.
56. Gómez-Outes A. Lecumberri R. Pozo C. Rocha E. (2009) New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol 7: 309–329.
57. Graefe-Mody E.U. Schühly U. Rathgen K. Stähle H. Leitner J.M. Jilma B. (2006) Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost 4: 1502–1509.
58. Gueret P. Krezel C. van Giersbergen P.L.M. Fuseau E. Petitou M. Neuhart E. (2009 / 2010) First human study with EP217609, a new synthetic parenteral neutralizable dual action anticoagulant. Pathophysiol Haemos Thromb 37(Suppl. 1): P 177 [abstract].
59. Guerrini M. Shriver Z. Bisio A. Naggi A. Casu B. Sasisekharan R. et al (2009) The tainted heparin story: an update. Thromb Haemost 102: 907–911.
60. Guertin K.R. Choi Y.M. (2007) The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 14: 2471–2481.
61. Gustafson M.E. Junger K.D. Wun T.C. Foy B.A. Diaz-Collier J.A. Welsch D.J. et al (1994) Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant. E. coli. Protein Expr Purif 5: 233–241.
62. Harenberg J. Jörg I. Vukojevic Y. Mikus G. Weiss C. (2008 a) Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 64: 555–563.
63. Harenberg J. Vukojevic Y. Mikus G. Joerg I. Weiss C. (2008 b) Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 6: 890–892.
64. Harenberg J. (2009) Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 102: 811–815.
65. Hartman D.L. Bernard G.R. Helterbrand J.D. Yan S.B. Fisher C.J. (1998) Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med 24(Suppl. 1): S 77 [abstract].
66. Heit J.A. (2008) The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 28: 370–372.
67. Henry B.L. Monien B.H. Bock P.E. Desai U.R. (2007) A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 282: 31891–31899.
68. Henry B.L. Connell J. Liang A. Krishnasamy C. Desai U.R. (2009 a) Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function. J Biol Chem 284: 20897–20908.
69. Henry B.L. Thakkar J.N. Martin E.J. Brophy D.F. Desaiac U.R. (2009 b) Characterization of the plasma and blood anticoagulation potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coag Fibrinol 20: 27–34.
70. Henry B.L. Abdel Aziz M. Zhou Q. Desai U.R. (2010) Sulfated, low-molecular-weight lignins are potent inhibitors of plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies. Thromb Haemost 103: 507–515.
71. Herbert J.M. Hérault J.P. Bernat A. van Amsterdam R.G. Lormeau J.C. Petitou M. et al (1998) Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91: 4197–4205.
72. Hermans C. Claeys D. (2006) Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 22: 471–481.
73. Hinder M. Paccaly A. Frick A. Shukla U. Simcox K. Miller B. et al (2005) Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. Thromb Haemost 93: 794–795.
74. Hinder M. Frick A. Jordaan P. Hesse G. Gebauer A. Maas J. et al (2006 a) Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther 80: 691–702.
75. Hinder M. Frick A. Rosenburg R. Hesse G. Ozoux M.L. Laux V. et al (2006 b) Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. Thromb Haemost 95: 224–228.
76. Hirsh J. Bauer K.A. Donati M.B. Gould M. Samama M.M. Weitz J.I. for the American College of Chest Physicians (2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 141S–159S.
77. Holsinger L.J. Shrader B. Magill C. Bremer M. Kattler J. Janc J. et al (2006) Small molecule-mediated inhibition of Factor VIIa catalytic activity blocks fVIIa:TF cellular signaling and chemokine secretion in human tumor cell lines. Proc Amer Assoc Cancer Res 47: Abstract #4708.
78. Hoppensteadt D. Jeske W. Walenga J.M. Fareed J. (2008) AVE5026: A new hemisynthetic ultra low molecular weight heparin with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis. J Clin Oncol 26(Suppl): 14653 [abstract].
79. Humphries J. Lattimer C. Smith A. McGuinness C.L. Whitton C. Gaffney P.J. et al (1997) High and constant plasma levels of tissue plasminogen activator and PEG-Hirudin can be achieved by subcutaneous delivery. Thromb Res 87: 123–129.
80. Hutabarat R.M. McCauley T. Makim A. Lewis S. Olsen K. Wagner-Whyte J. et al (2007) Pharmacokinetic / pharmacodynamic profile of a novel aptamer direct thrombin inhibitor in cynomolgus monkeys and Yorkshire pigs following a single IV bolus administration. J Thromb Haemost 5(Suppl. 2): P-S-072 [abstract].
81. Jacquemin M. Benhida A. Peerlinck K. Desqueper B. Vander Elst L. Lavend'homme R. et al (2000) A human antibody directed to the factor VIII C 1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 95: 156–163.
82. Jacquemin M. Radcliffe C.M. Lavend'homme R. Wormald M.R. Vanderelst L. Wallays G. et al (2006) Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. J Thromb Haemost 4: 1047–1055.
83. Jacquemin M. Stassen J.M. Saint-Remy J.M. Verhamme P. Lavend'homme R. VanderElst L. et al (2009) A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons. J Thromb Haemost 7: 429–437.
84. Kearon C. Comp P. Douketis J. Royds R. Yamada K. Gent M. (2005) Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 3: 962–968.
85. Kearon C. Kahn S.R. Agnelli G. Goldhaber S. Raskob G.E. Comerota A.J. for the American College of Chest Physicians (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 454S–545S.
86. Keefe A.D. Pai S. Ellington A. (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9: 537–550.
87. Kishimoto T.K. Qi Y.W. Long A. Capila I. Sasisekharan R. Guerrero L. et al (2009) M118–a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb Haemost 102: 900–906.
88. Kretz C.A. Cuddy K.K. Stafford A.R. Fredenburgh J.C. Roberts R. Weitz J.I. (2010) HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. Thromb Haemost 103: 83–93.
89. Lassen M.R. Agnelli G. Fisher W. George D. Kakkar A. Mismetti P. et al (2009 / 2010) The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective knee replacement surgery. Pathophysiol Haemos Thromb 37(Suppl. 1): OC 331 [abstract].
90. Lassen M.R. Dahl O.E. Mismetti P. Destrée D. Turpie A.G. (2009) AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study. J Thromb Haemost 7: 566–572.
91. Laterre P.F. (2008) Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Crit Care 12(Suppl. 6): S4–S4.
92. Laterre P.F. Opal S.M. Abraham E. LaRosa S.P. Creasey A.A. Xie F. et al (2009) A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 13: R36–R36.
93. Lee A. Agnelli G. Büller H. Ginsberg J. Heit J. Rote W. et al (2001) Dose–response study of recombinant factor VIIa / tissue factor inhibitor recombinant nematode anticoagulant protein c 2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104: 74–78.
94. Leitner J.M. Jilma B. Mayr F.B. Cardona F. Spiel A.O. Firbas C. et al (2007) Pharmacokinetics and pharmacodynamics of the dual FII / FX inhibitor BIBT 986 in endotoxin-induced coagulation. Clin Pharmacol Ther 81: 858–866.
95. Ma Q. Fareed J. (2004) Idraparinux sodium. Sanofi-Aventis. IDrugs 7: 1028–1034.
96. Mackman N. (2008) Triggers, targets and treatments for thrombosis. Nature 451: 914–918.
97. MacLeod R. Crosby J. Zhao C. Gao D. May C. Zhang H. et al (2009) Pharmacological characterization and structure activity relationship of FXI antisense oligonucleotides in cynomolgus monkeys. Blood (ASH Annual Meeting Abstracts) 114: Abstract 2101.
98. Mann K.G. (2005) The challenge of regulating anticoagulant drugs: focus on warfarin. Am Heart J 149(1 Suppl): S36–S42.
99. Mann J. Kuranoff S.J. Navarro I. Russo J. (2006) PEG-Musirudin (SPP200) effectively decreases vascular graft occlusions in patients on chronic hemodialysis. J Am Soc Nephrol 17: F-PO769 [abstract].
100. Martin G. Brunkhorst F.M. Janes J.M. Reinhart K. Sundin D.P. Garnett K. et al (2009) The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 13: R103–R103.
101. Maruyama I. (1999) Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 82: 718–721.
102. Mayer S.A. Brun N.C. Begtrup K. Broderick J. Davis S. Diringer M.N. et al (2008) Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358: 2127–2137.
103. Melloni C. Fier I. Roach J. Kosinski A.S. Broderick S. Sigmon K. et al (2009) Design and rationale of the Evaluation of M 118 IN pErcutaNeous Coronary int Ervention (EMINENCE) trial. Am Heart J 158: 726–733.
104. Michota F. Merli G. (2005) Anticoagulation in special patient populations: are special dosing considerations required? Cleve Clin J Med 72(Suppl. 1): S37–S42.
105. Mohri M. Gonda Y. Oka M. Aoki Y. Gomi K. Kiyota T. et al (1997) The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 8: 274–283.
106. Mohri M. Sugimoto E. Sata M. Asano T. (1999) The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost 82: 1687–1693.
107. Moll S. Lindley C. Pescatore S. Morrison D. Tsuruta K. Mohri M. et al (2004) Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2: 1745–1751.
108. Monia B. Zhang H. Zhao C. Siwkowski A. Freier S. Witchell D. (2007) ISIS 401025, a second generation antisense oligonucleotide targeting prothrombin, inhibits plasma prothrombin level and promotes anticoagulation in mice. Circulation 116(16 Suppl): Abstract 716.
109. Monien B.H. Henry B.L. Raghuraman A. Hindle M. Desai U.R. (2006) Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg Med Chem 14: 7988–7998.
110. Moons A.H. Peters R.J. Bijsterveld N.R. Piek J.J. Prins M.H. Vlasuk G.P. et al (2003) Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor / factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 41: 2147–2153.
111. Mouret P. Agnelli G. Fisher W. George D. Kakkar A. Lassen M.R. et al (2009 / 2010) The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Pathophysiol Haemos Thromb 37(Suppl.1): OC 316 [abstract].
112. Müller J. Wulffen B. Pötzsch B. Mayer G. (2007) Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer. Chembiochem 8: 2223–2226.
113. Müller J. Freitag D. Mayer G. Pötzsch B. (2008) Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 6: 2105–2112.
114. Murphy G.S. Marymont J.H. (2007) Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 21: 113–126.
115. Nadel S. Goldstein B. Williams M.D. Dalton H. Peters M. Macias W.L. et al (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369: 836–843.
116. Nakashima M. Kanamaru M. Umemura K. Tsuruta K. (1998) Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 38: 40–44.
117. Nelson D.A. Nelson K.T. Miller M.W. Dupe R. Chahwala S.B. Kennedy A. et al (2008) Pharmacodynamic and efficacy profile of TGN 255, a novel direct thrombin inhibitor, in canine cardiopulmonary bypass and simulated mitral valve repair. J Extra Corpor Technol 40: 116–122.
118. Nybo M. Madsen J.S. (2008) Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 103: 192–196.
119. Paccaly A. Ozoux M.L. Chu V. Simcox K. Marks V. Freyburger G. et al (2005) Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost 94: 1156–1163.
120. Paty I. Trellu M. Destors J.M. Cortez P. Boëlle E. Sanderink G. (2010) Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 8: 722–729.
121. PERSIST Investigators (2004) A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2: 47–53.
122. Petitou M. Nancy-Portebois V. Dubreucq G. Motte V. Meuleman D. de Kort M. et al (2009) From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 102: 804–810.
123. Pharmacyclics (2009) Factor VIIa inhibitor executive summary, September 2009, www.pharmacyclics.com.
124. Pöschel K.A. Bucha E. Esslinger H.U. Nörtersheuser P. Jansa U. Schindler S. et al (2000) Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. Kidney Int 58: 2478–2484.
125. Pöschel K.A. Bucha E. Esslinger H.U. Ulbricht K. Nörtersheuser P. Stein G. et al (2004) Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. Kidney Int 65: 666–674.
126. Prescott, J., Thiemann, P. and Loury, D. (2008) PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC 3 pancreatic adenocarcinoma xenograft tumors. In: Proceedings of the 99th AACR Annual Meeting, 12–16 April 2008, San Diego, CA, Abstract #5669.
127. Rao S.V. Melloni C. Myles-Dimauro S. Broderick S. Kosinski A.S. Kleiman N.S. et al (2010) Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M 118 IN pErcutaNeous Coronary int Ervention (EMINENCE) Trial. Circulation 121: 1713–1721.
128. Rusconi C.P. Kornbrust D. Zelenkofske S.L. (2010) Subcutaneous factor IXa inhibitor provides prolonged anticoagulation: The first successful subcutaneous application of an aptamer. J Am Coll Cardiol 55(10A): A172.E1618 [abstract].
129. Rusconi C.P. Scardino E. Layzer J. Pitoc G.A. Ortel T.L. Monroe D. et al (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419: 90–94.
130. Sabatine M.S. Antman E.M. Widimsky P. Ebrahim I.O. Kiss R.G. Saaiman A. et al (2009) Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 374: 787–795.
131. Saito H. Maruyama I. Shimazaki S. Yamamoto Y. Aikawa N. Ohno R. et al (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5: 31–41.
132. Sasisekharan R. Shriver Z. (2009) From crisis to opportunity: a perspective on the heparin crisis. Thromb Haemost 102: 854–858.
133. Savi P. Herault J.P. Duchaussoy P. Millet L. Schaeffer P. Petitou M. et al (2008) Reversible biotinylated oligosaccharides. A new approach for a better management of anticoagulant therapy. J Thromb Haemost 6: 1697–1706.
134. Schulman S. Kearon C. Kakkar A.K. Mismetti P. Schellong S. Eriksson H. et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342–2352.
135. Schumacher W.A. Seiler S.E. Steinbacher T.E. Stewart A.B. Bostwick J.S. Hartl K.S. et al (2007) Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 570: 167–174.
136. Schumacher W.A. Luettgen J.M. Quan M.L. Seiffert D.A. (2010) Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 30: 388–392.
137. Singh I. Smith A. Vanzieleghem B. Collen D. Burnand K. Saint-Remy J.M. et al (2002) Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 99: 3235–3240.
138. Steingrub, J.S., Cheatham, M.L., Woodward, B., Wang, H.T., Effron, M.B. and for the XEUS Investigators (2010) A prospective, observational study of Xigris Use in the United States (XEUS). J Crit Care, doi: 10.1016/j.jcrc.2010.03.009.
139. Suranyi M. Chow J.S. (2010) Review: anticoagulation for haemodialysis. Nephrology (Carlton) 15: 386–392.
140. Sutton J.C. Bolton S.A. Hartl K.S. Huang M.-H. Jacobs G. Meng W. et al (2002) Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 12: 3229–3233.
141. Tanaka K.A. Szlam F. Rusconi C.P. Levy J.H. (2009) In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost 101: 827–833.
142. Taylor F.B. Jr Chang A. Esmon C.T. D'Angelo A. Vigano-D'Angelo S. Blick K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918–925.
143. Teoh K.H. Young E. Blackall M.H. Roberts R.S. Hirsh J. (2004) Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 128: 211–219.
144. The Amadeus Investigators (2008) Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371: 315–321.
145. Trellu M. Perez Y. Ortiz J. Cheng S. Paty I. (2007) Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J Thromb Haemost 5(Suppl.2): P-T-678 [abstract].
146. Turpie A.G.G. Agnelli G. Fisher W. George D. Kakkar A. Lassen M.R. et al (2009 / 2010) Benefit-to-risk profile of the ultra-low-molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE): a meta-analysis of 3 major orthopaedic surgery studies. Pathophysiol Haemos Thromb 37(Suppl. 1): OC 332 [abstract].
147. van de Werf F. Bax J. Betriu A. Blomstrom-Lundqvist C. Crea F. Falk V. et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29: 2909–2945.
148. van Doormaal F.F. Cohen A.T. Davidson B.L. Decousus H. Gallus A.S. Gent M. et al (2010) Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the van Gogh DVT trial. Thromb Haemost 104: 86–91.
149. van Gogh Investigators, Buller H.R. Cohen A.T. Davidson B. Decousus H. Gallus A.S. et al (2007 a) Idraparinux vs. standard therapy for venous thromboembolic disease. N Engl J Med 357: 1094–1104.
150. van Gogh Investigators, Buller H.R. Cohen A.T. Davidson B. Decousus H. Gallus A.S. et al (2007 b) Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357: 1105–1112.
151. van Ryn J. Kink-Eiband M. Hauel N. Priepke H. Wienen W. (2007) Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma. Blood 110: Abstract 1884.
152. Vavra K.A. Lutz M.F. Smythe M.A. (2010) Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother 44: 718–726.
153. Verhamme P. Verhaeghe R. Ageno W. de Deene A. Glazer S. Prins M. et al (2009 / 2010) Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery. Pathophysiol Haemos Thromb 37(Suppl. 1): P 509 [abstract].
154. Verhamme P. Pakola S. Jensen T.J. Berggren K. Sonesson E. Saint-Remy J.M. et al (2010) Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 32: 1205–1220.
155. Vignoli A. Marchetti M. Cantalino E. Russo L. Balducci D. Falanga A. (2007) Low-molecular weight heparin (LMWH) bemiparin and ultra-low-MWH RO-14 inhibit lung, breast and leukemia cancer cell-induced endothelial angiogenesis. Thromb Res 120(Suppl. 2): PO-13 [abstract].
156. Viskov C. Just M. Laux V. Mourier P. Lorenz M. (2009) Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 7: 1143–1151.
157. Vlasuk G.P. Bradbury A. Lopez-Kinninger L. Colón S. Bergum P.W. Maki S. et al (2003) Pharmacokinetics and anticoagulant properties of the factor VIIa tissue factor inhibitor recombinant Nematode Anticoagulant Protein c 2 following subcutaneous administration in man: dependence on the stoichiometric binding to circulating factor X. Thromb Haemost 90: 803–812.
158. Vreeland, S. (2010) Synthesis of clavatadine A. Proceedings of the 15th Annual Symposium on University Research and Creative Expression, session 40, poster 24. Available at: www.cwu.edu/∼source/source_2010_Program.pdf (accessed 26 July 2010).
159. Wagner-Whyte J. Khuri S.F. Preiss J.R. Kurz J.C. Olson K. Hatala P. et al (2007) Discovery of a potent, direct thrombin inhibiting aptamer. J Thromb Haemost 5(Suppl. 2): P-S-067 [abstract].
160. Wang Y. Mealy N. Serradell N. Bolos J. Rosa E. (2007) Flovagatran sodium. Drugs Fut 32: 310–311.
161. Warkentin T.E. Greinacher A. Koster A. Lincoff A.M. for the American College of Chest Physicians (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 340S–380S.
162. Waters E.K. Richardson J. Schaub R.G. Kurz J.C. (2009) Effect of NU 172 and bivalirudin on ecarin clotting time in human plasma and whole blood. J Thromb Haemost 7(Suppl.2): PP-WE-168 [abstract].
163. Wong P.C. Jiang X. (2010) Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104: 302–310.
164. Wong P.C. Luettgen J.M. Rendina A.R. Kettner C.A. Xin B. Knabb R.M. et al (2010) BMS-593214, an active site-directed factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies. Thromb Haemost 104: 261–269.
165. World Health Organization (2009) WHO drug information 23: 74. Available at: http://www.who.int/medicines/publications/druginformation/en/ (accessed 24 June 2010).
166. Yan S.B. Brandt J.T. Correll N.L. Um S.L. Bourdage J.S. (2009) Evaluation of anti-activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alpha (activated). J Thromb Haemost 7: 1787–1794.
167. Yin E.T. Wessler S. (1970) Heparin-accelerated inhibition of activated factor X by its natural inhibitor. Biochem Biophys Acta 201: 387–390.
168. Zelenkofske, S.L., Rusconi, C.P., Damiento, C.M., Wargin, W., Medlock, M. and Becker, R. (2010) Subcutaneous RB006, a direct FIXa inhibitor provides prolonged anticoagulation with rapid reversal; the first clinical experience with the REG 2 system. In Proceedings of the ATVB 2010. E-poster: P624. Available at: http://aha.scientificposters.com/atvb (accessed 22 June 2010).
169. Zhang, H., Löwenberg, E.C., Crosby, J.R., Macleod, A.R., Zhao, C., Gao, D., et al. (2010) Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood, doi: 10.1182/blood-2010-04-277798.
170. Zhang Z. Weïwer M. Li B. Kemp M.M. Daman T.H. Linhardt R.J. (2008) Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 51: 5498–5501.